Belite Bio is a clinical-stage biopharmaceutical company developing Tinlarebant, an oral therapy targeting retinal degenerative diseases such as Stargardt disease and geographic atrophy by reducing toxic accumulation in the eye. The company addresses significant unmet medical needs in patients suffering from these conditions, with ongoing Phase 3 clinical trials to evaluate the therapy's efficacy and safety.
Funding
$28.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Retinal degenerative diseases, such as Stargardt disease and geographic atrophy (GA), lead to vision loss due to the accumulation of toxic metabolites in the eye. There is a significant unmet medical need for effective therapies to address these conditions and prevent progressive blindness.
Solution
Belite Bio is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for retinal degenerative diseases. Their lead candidate, Tinlarebant (LBS-008), is an oral therapy designed to reduce the accumulation of toxins in the eye that cause Stargardt disease and contribute to GA, addressing the underlying pathology of these conditions. Tinlarebant modulates the delivery of vitamin A to the eye, reducing the buildup of toxic metabolites to preserve vision. The company has completed a Phase 2 study in adolescent Stargardt disease subjects and is currently conducting Phase 3 trials for both Stargardt disease and GA to evaluate the efficacy and safety of Tinlarebant.
Target Audience
The primary target audience includes patients suffering from retinal degenerative diseases such as Stargardt disease and geographic atrophy (GA), as well as ophthalmologists and medical professionals specializing in retinal disorders.
Features
- Oral, once-daily tablet formulation for convenient administration
- Targets the RBP4 (Retinol Binding Protein 4) pathway to reduce toxin accumulation in the eye
- -正在进行针对Stargardt疾病的III期临床试验（DRAGON和DRAGON II）
- -正在进行针对地图状萎缩的III期临床试验（PHOENIX）
- Orphan Drug Designation in the United States, Europe, and Japan
- Rare Pediatric Disease (RPD) designation and Fast Track Designation in the US
- Sakigake (Pioneer Drug) Designation in Japan